Talphera (NASDAQ:TLPH) Stock Rating Upgraded by Wall Street Zen

Talphera (NASDAQ:TLPH) was upgraded by equities researchers at Wall Street Zen to a “hold” rating in a research note issued to investors on Saturday.

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Talphera in a research note on Wednesday, October 8th. Two investment analysts have rated the stock with a Strong Buy rating, two have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Talphera currently has a consensus rating of “Buy” and a consensus target price of $5.00.

Talphera Trading Up 8.1%

Shares of TLPH opened at $1.34 on Friday. The firm’s 50-day moving average price is $0.96 and its 200-day moving average price is $0.64. The firm has a market capitalization of $62.46 million, a price-to-earnings ratio of -3.35 and a beta of 0.03. Talphera has a 1-year low of $0.38 and a 1-year high of $1.45.

Talphera (NASDAQ:TLPH) last announced its earnings results on Thursday, August 14th. The company reported ($0.10) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.02. On average, research analysts forecast that Talphera will post -0.64 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Talphera stock. AIGH Capital Management LLC acquired a new stake in shares of Talphera, Inc. (NASDAQ:TLPH) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 4,454,545 shares of the company’s stock, valued at approximately $3,979,000. Talphera comprises approximately 1.1% of AIGH Capital Management LLC’s investment portfolio, making the stock its 24th largest position. AIGH Capital Management LLC owned approximately 9.56% of Talphera as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 37.67% of the company’s stock.

Talphera Company Profile

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.